Background. This cost-effectiveness analysis of imatinib in British Columbia Cancer Agency (BCCA) patients with advanced gastrointestinal stromal tumors (GIST) was performed to justify funding.
Patients and Methods. A pragmatic, retrospective review identified BCCA patients with advanced GIST who received imatinib or historical treatment during successive, pre-specified time periods. Primary outcome was the cost-effectiveness (CE) of imatinib based on median overall survival (MOS). Secondary outcomes were cost-effectiveness based on median progression-free survival (PFS) and comparison to literature efficacy. This study took the BCCA perspective. Sensitivity analyses varying effectiveness over the 95% confidence interval (CI), cost to its extremes, discounting level at 0, 3, and 5%, and substituting life expectancy for MOS were performed.
Results. Forty-six and 47 patients in the imatinib and historical groups respectively showed MOS with imatinib to be 66.7 months (95%CI 61.7— infinity) compared to 7.7 (95%CI 6.0—12.6) in the historical group. Median-PFS were 45.3 months (95%CI 24.4—infinity) and 5.6 (95%CI 3.5—8.5) respectively. Imatinib effectiveness was similar to literature reports. The annual incremental CE ratio for imatinib was $15,882 CDN per median life year gained and $23,603 CDN per median year of PFS.
Conclusions. Imatinib for advanced GIST seems cost-effective in BC. Results were robust across a range of sensitivity analyses. J Oncol Pharm Practice (2008) 14: 105—112.
BC Cancer registry.GIST's and leiomyosarcomas of GI tract, 2001.
2.
Miettinen M. , Lasota J.Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis . Virchows Arch2001; 438: 1-12.
3.
Van Roggen JFG , Van Velthuysen MLF , Hogendoorn PCW.The histopathological differential diagnosis of gastrointestinal tumors . J Clin Pathol2001; 54: 96-103.
4.
Berman J. , O'Leary TJPerspectives in pathology: gastrointestinal stromal tumor workshop . Hum Pathol2001; 32: 578-82.
5.
Plaat BEC , Hollema H. , Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins . J Clin Oncol2000; 18: 3211-20.
6.
Benjamin RSShould patients with advanced sarcomas be treated with chemotherapy?Eur J Cancer1998; 34: 958-62.
7.
Bedikian AY , Valdivieso M. , Khankhanian N. et al. Chemotherapy for sarcoma of the stomach . Cancer Treat Rep1979; 63: 411-14.
8.
Edmonson JH , Marks RS , Buckner JC et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas . Cancer Invest2002; 20: 605-12.
9.
Dematteo RP , Heinrich MC , El-Rifai WM , Demetri G.Clinical management of gastrointestinal stromal tumors: before and after STI-571 . Hum Pathol2002; 33: 466-77.
10.
Nilsson B. , Bumming P. , Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era . Cancer2005; 103: 821-29.
11.
Kitamura Y. , Hayashi K.Pushing the imatinib envelope . Lancet2004; 364: 1101-02.
12.
Demetri GD , Von Mehren M. , Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors . N Engl J Med2002; 347: 472-80.
13.
Joensuu H. , Roberts P. , Sarlomo-Rikala M. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor . N Engl J Med2001; 344: 1052-56.
14.
Van Oosterom AT , Judson IR , Verweij J. et al. Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group . Eur J Cancer2002; 35 (suppl 5): S83-87.
15.
Benjamin RS , Rankin C. , Fletcher C. et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results . Proc Am Soc Clin Oncol2003; 22: (abstract 3271).
16.
Verweij J. , Casali PG , Zalcberg J. et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG . Proc Am Soc Clin Oncol2003; 22: (abstract 3272).
17.
Blay JY , Bonvalot S. , Casali P. et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 march 2004, under the auspices of ESMO . Ann Oncol2004; 16: 566-78.
18.
Taylor SCM , Uyeno KT , O'Reilly SE et al. Development of a systemic therapy costing model in a provincial oncology centre (abstract) . Eur J Cancer2000 ; 36 (Suppl 3): S26 .
19.
Taylor SCM , Chow L.Development of a pharmacoeconomics service in a provincial oncology program (abstract) . Eur J Cancer1997; 33 (Suppl 9): S31 .
20.
Greanya ED , Taylor SCM , Hu F. et al. Temozolamide for malignant gliomas in British Columbia: a population-based cost-effectiveness analysis . J Oncol Pharm Practice2004; 10: 201-09.
21.
Wilson J. , Connock M. , Song F. et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation . Health Technol Assess2005; 9(25): 1-142.
22.
Uyl-de Groot CA , Gianccone G.Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?Curr Opin Oncol2005; 17: 392-96.
23.
Gafni A. , Birch S.Incremental cost-effectiveness ratios (ICERs): the silence of the lambda . Soc Sci Med2006; 62: 2091-2100.
24.
Verweij J. , Casali PG , Zalcberg J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial . Lancet2004; 364: 1127-34.
